Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19132988 | 0.76 | CYP2D6 (0.32) | CHRM1 | |
| SCHEMBL24199566 | 0.75 | TSHR (0.36) | LMNAPOLBTSHRCHRM2CHRM4 | |
| SCHEMBL21245968 | 0.73 | ESR1 (0.34) | — | |
| SCHEMBL23776206 | 0.72 | OPRD1 (0.37) | — | |
| SCHEMBL21536087 | 0.68 | AURKA (0.33) | KDM4EALDH1A1 | |
| SCHEMBL22725661 | 0.68 | TSHR (0.38) | KDM4ELMNACXCR4ALDH1A1TSHR | |
| SCHEMBL15316713 | 0.68 | NOS3 (0.34) | KDM4ETSHR | |
| SCHEMBL25003875 | 0.67 | TSHR (0.41) | LMNACXCR4SMN1; SMN2TSHRCHRM2 | |
| SCHEMBL19514113 | 0.67 | NOS1 (0.40) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21888308 | 0.66 | TSHR (0.36) | CXCR4POLBTSHRCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | KDM4E 253/4885LMNA 3104/4885CXCR4 3714/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | KDM4E 253/4885LMNA 3104/4885CXCR4 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.